AddedRisk Factors
We rely on our internal technology systems and websites to run our business as well as our or our third-party partners’ physical facilities, such as our R&D or manufacturing premises. In addition, we rely on third-party hosted services. A disruption, infiltration or failure of these systems, facilities or third-party hosted services in the event of a hurricane, tsunami, tornado,
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedRisk Factors
Escalating geopolitical tensions or military conflict between India and Pakistan could disrupt our operations, supply chain, or workforce in the region, potentially resulting in production delays, increased costs, or reduced availability of key materials. Any sustained instability in the region could also impair our ability to maintain reliable logistics, regulatory continuity, or business continuity planning across affected jurisdictions.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedRisk Factors
The recently enacted OBBBA introduces significant changes to U.S. healthcare programs, including Medicaid, Medicare, and Affordable Care Act marketplaces. These changes may reduce federal healthcare spending and alter eligibility requirements, which could result in fewer individuals having health coverage. Reduced coverage could lead to lower prescription volumes and decreased demand for our products. Additionally, OBBBA includes provisions that may increase compliance obligations and administrative complexity for manufacturers participating in government programs. These changes could require additional resources and may increase our costs. The full impact of OBBBA is uncertain and will depend on implementation details and potential state-level actions. These developments could adversely affect our business, results of operations, or financial condition.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RemovedRisk Factors
Revenues and gross margin derived from generic pharmaceutical products often follow a pattern based on regulatory and competitive factors that we believe are unique to the generic pharmaceutical industry. As the patent(s) for a brand name product
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
We depend to a large extent on third-party suppliers and distributors for the raw materials for our products, particularly the chemical compounds comprising the APIs that we use to manufacture our products, as well as for certain finished goods. A prolonged interruption in the supply of such products could have a material adverse effect on our business, financial position and results of operations.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
The U.S. and various foreign governments have established certain trade and tariff requirements. From time to time, the U.S. government has indicated a willingness to revise or renegotiate tariffs on certain goods imported into the U.S. Since we rely on APIs, packaging and other components and finished pharmaceutical products from China, India, and certain countries in the European Union, such steps, if adopted, could adversely impact our business, increase our costs, and make our products less competitive.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
On February 1, 2025, President Trump announced a 10% additional tariff on imports from China and has expressed the possibility of imposing tariffs on imports from the European Union and India. In addition, on February 13, 2025, President Trump announced a plan to establish reciprocal tariffs with nations that impose tariffs on U.S. products, and directed relevant segments of the U.S. government to assess harm of non-reciprocal trade arrangements and to generate a report of that assessment within 180 days. Reciprocal tariffs may be imposed prior to completion of the report. There also have been statements by the Trump Administration regarding a 25% tariff on pharmaceutical products. For the year ending December 31, 2025, we estimate the impact of tariffs currently imposed on our imports from China will not be material. We are unable to estimate the impacts of any tariffs that have not yet been imposed by the U.S. government.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
Maintaining the secrecy of confidential, proprietary, and/or trade secret information is important to our competitive business position. We continually assess these threats and make investments to increase internal protection, detection, and response
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
subject to change in the future. In addition, we could be criticized for the scope or nature of such initiatives or goals, or for any revisions to these goals. If our ESG-related data, processes and reporting are incomplete or inaccurate, or if we fail to achieve progress with respect to our goals within the scope of ESG on a timely basis, or at all, our reputation, business, financial performance and growth could be adversely affected.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedRisk Factors
The pharmaceutical industry has We also in recent years been the subject face risks resulting from public criticism of significant publicity regarding the drug pricing of pharmaceutical products more generally, including publicity and pressure resulting from prices charged by competitors and peer companies for new products as well as price increases by competitors and peer companies on older products that the public has deemed excessive.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
The majority of our products are produced at a limited number of locations, and a business interruption at one or more of these locations or within our supply Supply chain disruptions could have a material adverse effect on our business, financial position and results of operations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
As of December 31, 2024, 2025, we had $2.6 $2.7 billion of total indebtedness, comprised of $2.3 billion, $192.0 million $2.1 billion and $100.0 $600.0 million in borrowings outstanding on the Term Loan Due 2028, Term Loan 2032 and Senior Notes Due 2025 and Amended New Revolving Credit Facility, 2032, respectively.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
We are a party to a tax receivable agreement (“TRA”) with each of the members of the group, together with their affiliates and certain assignees, who owned Amneal when it was a private company (“Members” or the “Amneal Group”), dated May 4, 2018. Group.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
We may also communicate certain initiatives and goals, goals regarding environmental matters, diversity, workforce management and talent retention, responsible sourcing and sourcing, social investments and or other ESG related matters, sustainability-related matters in our responsible business report or other public disclosures. documents.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
We may experience Customer consolidation could cause declines in the sales volume and the prices of our products as a result of the continuing trend of consolidation of certain customer groups, products, which could have a material adverse effect on our business, financial position and results of operations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
As of December 31, 2024, 2025, we had an ability to borrow up to an additional $523.2 $678.2 million under our revolving credit facilities, comprised of $495.2 $595.2 million and $28.0 $83.0 million of available capacity under the Amended New 2025 Revolving Credit Facility (as defined and the Amended Rondo Revolving Credit Facility, respectively. described in Note 14.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
We generally begin our development activities for Developing a new generic drug product often starts several years in advance of the patent expiration date of before the brand-name drug equivalent. equivalent patent expires.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we are unable to timely obtain these licenses on commercially reasonable terms, our ability to commercially market our products may be inhibited or prevented, which could have a material adverse effect on our business, results of operations and financial condition.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
The “Pillar One” global profit allocation proposal would not apply currently applies only to us, because it the largest and most profitable multinational enterprises and, as proposed, generally applies to companies with global revenues exceeding €20 billion (approximately $21 $23 billion using the exchange rate as of December 31, 2024). 2025).
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, the European Union (“EU”) enacted the Corporate Sustainability Reporting Directive (“CSRD”) legislation in January 2023 which requires certain reporting and disclosure starting during the first quarter of 2026 of calendar year 2025 data relating to ESG sustainability matters for companies whose business and assets exceed certain thresholds within EU countries. countries, including non-EU groups with EU subsidiaries.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
We expect to make interest payments totaling $226.9 $193.9 million, excluding the impact of our interest rate swap and borrowings under our Amended New Revolving Credit Facility, swap, during 2025 2026 related to the Term Loan Due 2028. 2032 and Senior Notes Due 2032.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If we are unable to cannot successfully develop or commercialize new products, our operating results will suffer.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
For example, in 2025, we expect to lose lost exclusivity for RYTARY®, an extended-release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Changes in trade policy, including the imposition of tariffs may adversely affect our business, results of operations and financial condition.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
The results of clinical trials may not be indicative of results that would be obtained from large scale testing.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Failure to address AI risks will could reduce our ability to deliver strategic objectives.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
These opposing views may also be adopted by certain of our investors.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Certain jurisdictions Some markets have, from time to time, experienced instances of civil unrest and hostilities, both internally and with neighboring countries.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
The Amneal Group has control significant influence over all matters submitted to our stockholders for approval, including changes in capital structure, transactions requiring stockholder approval under Delaware law and corporate governance, subject to the terms of the Stockholders Agreement relating to the Amneal Group's agreement to vote in favor of directors not designated by the Amneal Group and such other matters that are set forth in the Stockholders Agreement.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
poisoning in adults. RYTARY® is indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. UNITHROID®, indicated for the treatment of hypothyroidism, is sold under a license and distribution agreement with Jerome Stevens Pharmaceuticals, Inc.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
New product launches are an important growth driver. Brekiya® autoinjector, approved by the FDA in May 2025 and launched in the U.S. in October 2025, is the first and only ready-to-use autoinjector formulation of dihydroergotamine mesylate indicated for the acute treatment of migraine, with or without aura, and for the acute treatment of cluster headache in adults.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
In 2025, CREXONT® continued to grow within our Specialty segment. CREXONT® was added to three large national formularies, which expanded total U.S. insurance coverage from about 30% of covered lives at the end of 2024 to over 50% at the end of 2025. In December 2025, we announced new positive interim results from our ongoing Phase 4 ELEVATE-PD study, including significant increases in daily “Good On” time and reductions in “Off” time.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
We are subject to certain trade and tariff requirements imposed by the U.S. and various foreign governments. The great majority of our net sales rely on FDF or API produced in the U.S. or India. We have limited reliance on imports from Europe and China, and no reliance on imports from Mexico or Canada.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
Since taking office in 2025, President Trump has announced a number of tariff actions, and while there are currently no reciprocal tariffs on pharmaceutical products imported into the U.S., this can change at any moment. On February 1, 2025, the Administration imposed a 10% tariff on all products from China under the International Emergency Economic Powers Act, (50 U.S.C. 1701 et seq) (the “IEEPA”), and related authorities as announced in the Federal Register Notice and Executive Order 14195 dated February 1, 2025 (as amended). On February 20, 2026, the Supreme Court of the United States issued an opinion
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
ruling that President Trump’s tariffs exceeded presidential authority under the IEEPA, which had the effect of invalidating the tariffs imposed thereunder to date.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
On April 14, 2025, the Department of Commerce Bureau of Industry and Security (“DOCBIS”) announced that it had initiated, as of April 1, 2025, a broad investigation under section 232 of the Trade Expansion Act to determine the effects on national security of imports of pharmaceuticals (i.e. FDF, API, key starting materials, derivatives, and medical countermeasures), including whether trade remedies such as tariffs should be imposed. This investigation covers both generic and brand products. On September 26, 2025, DOCBIS announced that it had initiated, as of September 2, 2025, a separate Section 232 national security investigation of imports of personal protective equipment, medical consumables (including syringes and intravenous bags), and medical equipment (including devices). These Section 232 investigations are ongoing. On February 20, 2026, President Trump imposed a 10% global tariff for 150 days under Section 122 of the Trade Act of 1974. FDF and API are exempt from the Section 122 tariff as of the date of this filing.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
Given the global nature of pharmaceutical supply chains, any changes to historically prevailing tariff requirements could impact us and our industry by increasing costs, affecting product availability, and/or disrupting supply chains. The Company is closely monitoring these tariff and trade developments and will take actions to reduce or minimize any material negative impact.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
On July 4, 2025, President Trump signed OBBBA, which includes a broad range of tax reform provisions affecting businesses, including, but not limited to, extending or making permanent certain business and international tax measures initially established under the 2017 Tax Cuts and Jobs Act and eliminating the requirement to capitalize and amortize U.S.-based research and experimental expenditures over five years, making these expenditures fully deductible in the period incurred. These provisions resulted in a reduction of the Company’s current income tax liabilities of $7.8 million during the year ended December 31, 2025.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
Other operating income for the year ended December 31, 2025 was primarily comprised of income earned from the India Production Linked Incentive Scheme for the Pharmaceutical Sector (the “PLI Scheme”).
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
On January 23, 2026, we determined that we will make effective our nationwide agreement to settle a substantial majority of the opioids-related claims brought against us by various states and subdivisions (the “Nationwide Opioids Settlement Agreement”), having previously secured sufficient participation by those states and subdivisions, including all eligible state and territorial Attorneys General and all subdivisions that previously sued us. The Nationwide Opioids Settlement Agreement was effective on January 29, 2026 and we made our first installment payment of $23.8 million to the trust administrator on that date. An additional installment payment of $12.1 million was made on February 26, 2026. Refer to Note 19. Commitments and Contingencies and Note 25. Subsequent Events for additional information.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
Beginning on January 1, 2026, the holders of the Rondo Class B Units have a put right to require us to purchase their units for a purchase price that is based on a multiple of Rondo’s earnings before income taxes, depreciation, and amortization subject to
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RemovedMD&A
Although we had a minority economic interest in Amneal prior to March 31, 2023, we were Amneal’s sole managing member, having the sole voting power to make all of Amneal’s business decisions and control its management. Therefore, we consolidated the financial statements of Amneal and its subsidiaries prior to the Reorganization. We recorded non-controlling interests for the portion of Amneal’s economic interests that we did not hold prior to the Reorganization.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
We have three reportable segments: Affordable Medicines (formerly known as Generics), Specialty, and AvKARE.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
During the fourth quarter of 2024, we changed the name of our Generics segment to “Affordable Medicines” to reflect the full product offering of the segment. The segment name change did not result in any change to the composition of our reportable segments and, therefore, did not result in any changes to our historical segment results.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
In process research and development (“IPR&D”) impairment charges of $30.8 million for the year ended December 31, 2023 were related to one Affordable Medicines asset and one Specialty asset, both of which experienced adverse clinical trials results in the fourth quarter of 2023 and resulted in significantly lower than expected future cash flows.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
The year-over-year variance of $13.6 million in change in fair value of contingent consideration for the year ended December 31, 2024 as compared to the prior year was primarily related to a reduction in promotional focus on LYVISPAHTM during the year ended December 31, 2023. Refer to Note 18. Fair Value Measurements for additional information.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
Affordable Medicines IPR&D impairment charges for the year ended December 31, 2023 were related to one asset that experienced adverse clinical trials results in the fourth quarter of 2023 and resulted in significantly lower than expected future cash flows.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
For the year ended December 31, 2023, the Affordable Medicines credit related to legal matters, net was $(0.1) million, comprised of $10.0 million received from the settlement of patent infringement matters, net of $3.9 million in charges associated with civil prescription opioid litigation, a $3.0 million charge for the settlement of a customer claim, and a $3.0 million charge for the settlement of commercial antitrust litigation.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
The year-over-year variance of $13.6 million in change in fair value of contingent consideration for the year ended December 31, 2024 as compared to the prior year was primarily related to a reduction in promotional focus on LYVISPAHTM during the year ended December 31, 2023. Refer to Note 18. Fair Value Measurements for additional information.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
Loan Due 2025, plus accrued interest thereon of $0.7 million, with $190.0 million of new borrowings under the Amended New Revolving Credit Facility and cash on hand.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
(2)A description of our Amended New Revolving Credit Facility is contained in Note 15. Debt. The table assumes the balance outstanding as of December 31, 2024 will be repaid or refinanced by December 31, 2025. The actual balance outstanding may fluctuate significantly in future periods. The interest rate on borrowings under the Amended New Revolving Credit Facility resets every 30, 90 or 180 days based on the term that we select. In January 2025, the Company paid the entire remaining principal balance of $192.0 million outstanding on its Term Loan Due 2025, plus accrued interest thereon of $0.7 million, with $190.0 million of new borrowings under the Amended New Revolving Credit Facility and cash on hand.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedMD&A
AvKARE cost of goods sold for the year ended December 31, 2024 2025 increased 25.7% 6.9% as compared to the prior year, and gross profit as a percentage of net revenue decreased to 15.6% for the year ended December 31, 2024 from 16.3% in the prior year primarily due to the higher sales in our government label channel and an increase in our inventory provision, partially offset by decreased sales through in our lower margin distribution channel and an increased inventory provision. channel.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Specialty cost of goods sold for the year ended December 31, 2024 decreased 5.3% 2025 increased 21.2% as compared to the prior year primarily due to a marketed product intangible asset an impairment charge of $34.1 million in 2023 related to reduced promotional focus on LYVISPAH®, partially offset by increased sales in our promoted products. a non-promoted product of $22.1 million (refer to Note 11.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The year-over-year decrease increase in net cash used in investing activities was primarily due to $12.0 million an increase in capital expenditures and deposits for future acquisition of property, plant, and equipment in the current year, partially offset by proceeds from the sale of a subsidiary in India to a subsidiary of Kashiv in April 2024 (refer to Note 23. the prior year.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Research and development (“R&D”) expenses for the year ended December 31, 2024 increased 16.3% 2025 decreased 2.4% from the prior year primarily due to an increase a decrease in in-licensing and upfront milestone payments of $30.0 $7.5 million, including $20.0 million associated with our exclusive license of Omalizumab (refer to Note 23. partially offset by an increase in employee compensation.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Specialty Affordable Medicines R&D expense for the year ended December 31, 2024 2025 decreased 40.3% 9.2% as compared to the prior year primarily due to reduced project spend decreases in in-licensing and upfront milestone payments of $8.6 $13.5 million and reduced infrastructure costs. project spend, partially offset by increased employee compensation.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
We test goodwill for possible Goodwill is not amortized; rather, it is subject to annual impairment annually testing during the fourth quarter, quarter of each year, or whenever more frequent testing if events or circumstances indicate that the carrying amount may not be recoverable.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Further testing is only required if the entity determines, If, based on the qualitative this assessment, we conclude that it is more likely than not that a reporting unit’s fair value is less than exceeds its carrying amount. amount, no further testing is required.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Specialty SG&A expense Selling, general and administrative (“SG&A”) expenses for the year ended December 31, 2024 2025 increased 24.4% 10.6% as compared to the prior year primarily due to increases in promotional employee compensation and launch costs associated with ONGENTYS® CREXONT® and CREXONT®. the Brekiya® autoinjector.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Affordable Medicines net revenue for the year ended December 31, 2024 2025 increased 14.5% 3.6% as compared to the prior year, primarily due to new products launched in 2024 2025 and 2023, 2024, which included biosimilars that contributed $59.7 million of year-over-year growth and other new products that contributed $144.1 $122.6 million of year-over-year growth, and strong volume growth, partially offset by price erosion.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Specialty Affordable Medicines SG&A expense for the year ended December 31, 2024 2025 increased 24.4% as by 9.9% compared to the prior year primarily due to increases in promotional employee compensation, costs associated with ONGENTYS® of our international expansion, and CREXONT®. shipping costs.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Specialty R&D expense for the year ended December 31, 2024 decreased 40.3% 2025 increased 59.2% as compared to the prior year primarily due to reduced project spend increased in-licensing and upfront milestone payments of $8.6 $6.0 million and reduced infrastructure costs. higher project spend.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Further testing is only required if the entity determines, based on the We may first perform a qualitative assessment, that assessment to determine whether it is more likely than not that a reporting unit’s fair value is less than its carrying amount.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesMD&A
Our Affordable Medicines segment includes approximately 270 over 280 product families covering an extensive range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches and topicals.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new